



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 1, 2015

Via E-mail

Mr. Simon Dingemans  
Chief Financial Officer  
GlaxoSmithKline plc  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS  
United Kingdom

**Re: GlaxoSmithKline plc  
Form 20-F for the Fiscal Year Ended December 31, 2014  
Filed February 27, 2015  
File No. 1-15170**

Dear Mr. Dingemans:

We have reviewed your May 6, 2015 response to our April 2, 2015 letter and have the following comment.

Please respond to this letter within 10 business days by providing the requested information or by advising us when you will provide the requested response. If you do not believe the comment applies to your facts and circumstances, please tell us why in your response. Please furnish us a letter on EDGAR under the form type label CORRESP that keys your response to our comment.

After reviewing the information you provide, we may have additional comments and/or request that you amend your filing.

Exhibit 15.2: GSK Annual Report 2014  
Notes to financial statements  
Note 14: Taxation, page 156

1. Please provide us proposed revised disclosure to be included in future periodic reports that explains the increase in tax rate associated with overseas operations and the decrease in tax rate associated with the benefit of intellectual property incentives consistent with your response to previous comment 1. In your disclosure, please identify the major tax jurisdictions involved and include a brief explanation of patent box regimes.

Mr. Simon Dingemans  
GlaxoSmithKline plc  
June 1, 2015  
Page 2

You may contact Mark Brunhofer, Senior Staff Accountant, at (202) 551-3638 or Lisa Vanjoske, Assistant Chief Accountant, at (202) 551-3614 if you have questions regarding the comments. In this regard, do not hesitate to contact me at (202) 551-3679.

Sincerely,

/s/ Jim B. Rosenberg

Jim B. Rosenberg  
Senior Assistant Chief Accountant